IGF-1R as an anti-cancer target-trials and tribulation

Chinese Journal of Cancer

Volumn 32, Issue 5, 2013, Pages 242-252

  Chen, Helen X ^a   Sharon, Elad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

IGF 1R; Insulin receptor

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; ANTIESTROGEN; AVE 1642; BIIB 022; BVP 51004; CARBOPLATIN; CETUXIMAB; CIXUTUMUMAB; CP 751 871; DALOTUZUMAB; DUSIGITUMAB; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FIGITUMUMAB; FULVESTRANT; GANITUMAB; GEMCITABINE; IRINOTECAN; LINSITINIB; MONOCLONAL ANTIBODY; NORDIHYDROGUAIARETIC ACID; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; R 1507; ROBATUMUMAB; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 228;

ADRENAL CORTEX CARCINOMA; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; COLON CANCER; COLORECTAL CANCER; DESMOPLASTIC SMALL ROUND CELL TUMOR; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN THERAPY; EWING SARCOMA; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; IGF1R GENE; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; ONCOGENE; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; THYMOMA; THYMUS CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG COMBINATIONS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; SARCOMA, EWING; SIGNAL TRANSDUCTION;

EID: 84877313224     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10263     Document Type: Review

References (95)

1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 2008,8:915-928.
2. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem, 2008,114:23-37.
3. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer, 2004,4:505-518.
4. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncol, 2002,63:317-332.
5. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res, 1999,253:1-6.
6. Clemmons DR. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol, 2006,6: 620-625.
7. LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab, 2007,3:302-310.
8. Nickerson T, Chang F, Lorimer D, et al. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res, 2001,61:6276-6280.
9. Cullen KJ, Yee D, Sly WS, et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res, 1990,50:48-53.
10. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-in duced cell death-proliferative and anti-ap optotic effects. Breast Cancer Res Treat, 1999,56:1-10.
11. Lee AV, Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother, 1995,49:415-421.
12. Peyrat JP, Bonneterre J. Type 1 IGF receptor in human breast diseases. Breast Cancer Res Treat, 1992,22:59-67.
13. Hassan AB, Macaulay VM. The insulin-like growth factor system as a therapeutic target in colorectal cancer. Ann Oncol, 2002,13:349-356.
14. Wu Y, Yakar S, Zhao L, et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res, 2002,62:1030-1035.
15. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effectorof multiple myeloma cell growth. Blood, 2000,96:2856-2861.
16. Gee JM, Robertson JF, Gutteridge E, et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer, 2005,12 Suppl 1:S99-S111.
17. Shin DH, Min HY, El-Naggar AK, et al. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-in sulin-like growth factor I receptor monoclonal antibody. Molecular Cancer Therapeutics, 2011,10:2437-2448.
18. Villanueva J, Vultur A, Lee JT, et al. Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R /PI3K. Cancer Cell, 2010,18:683-695.
19. Iravani S, Zhang HQ, Yuan ZQ, et al. Modification of insulin-like growth factor 1 receptor, c-Sr c, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol, 2003,34:975-982.
20. LeRoith D, Baserga R, Helman L, et al. Insulin-like growth factors and cancer. Ann Intern Med, 1995,122:54-59.
21. Berns EM, Klijn JG, van Staveren IL, et al. Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res, 1992,52:1036-1039.
22. De Souza AT, Hankins GR, Washington MK, et al. Frequent loss of heterozygosity on 6q at the mannose 6-ph osphate/ insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene, 1995,10:1725-1729.
23. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science, 2003,299:1753-1755.
24. Kaneda A, Feinberg AP. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res, 2005,65:11236-11240.
25. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-de pendent signaling and inhibits human tumor growth in vivo. Cancer Res, 2003,63:8912-8921.
26. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-ty pe 1 insulin-like growth factor receptor monoclonal antibody CP-75 1,871. Clin Cancer Res, 2005,11: 2063-2073.
27. Gao J, Chesebrough JW, Cartlidge SA, et al. Dual IGF-I/I I- neutralizing antibody MEDI-57 3 potently inhibits IGF signaling and tumor growth. Cancer Res, 2011,71:1029-1040.
28. Ji QS, Mulvihill M, Franklin M, et al. Properties of small molecule IGF-IR kinase inhibitors in preclinical models. AACR Meeting Abstracts, Apr 2007: 2373.
29. Ji QS, Mulvihill M, Rosenfeld-Franklin M, et al. Preclinical characterization of OSI-90 6: a novel IGF-1R kinase inhibitor in clinical trials. AACR Meeting Abstracts, Oct 2007: C192.
30. Morrione A, Valentinis B, Xu SQ, et al. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci U S A, 1997,94:3777-3782.
31. Milazzo G, Giorgino F, Damante G, et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res, 1992,52:3924-3930.
32. Zhang H, Pelzer AM, Kiang DT, et al. Down-re gulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res, 2007,67:391-397.
33. Tolcher AW, Sarantopoulos J, Patnaik A, et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor. J Clin Oncol, 2009,27:5800-5807.
34. de Bono JS, Attard G, Adjei A, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res, 2007,13:3611-3616.
35. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-75 1,871 in patients with refractory solid tumors. Clin Cancer Res, 2007,13:5834-5840.
36. Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the antiinsulinlike growth factor type 1 receptor monoclonal antibody CP-75 1,871 in patients with multiple myeloma. J Clin Oncol, 2008,26:3196-3203.
37. Seraj J, Tsai M, Wang Y, et al. Evaluation of pharmacodynamic properties of a fully human IGF-1 receptor antibody, SCH 717454, in healthy volunteers. AACR Meeting Abstracts, Apr 2009: 3615.
38. Tolcher AW, Patnaik A, Till E, et al. A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor 1 receptor) antagonist, in patients (pts) with advanced solid tumor (st). J Clin Oncol, 2008,26 suppl:abstr 3582.
39. Patel S, Pappo A, Crowley J, et al. A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. J Clin Oncol, 2009,27 suppl:abstr 10503.
40. Postel-Vinay S, Okuno S, Schuetze S, et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-75 1,871 in patients with sarcoma. EJC Supplements, 2008,6:122.
41. Rodon J, Patnaik A, Stein M, et al. A phase I study of q3w R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol, 2007, 25 suppl: abstr 3590.
42. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol, 2011,29:4541-4547.
43. Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol, 2012,30:1849-1856.
44. Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol, 2012,30:256-262.
45. Rothenberg ML, Tolcher A, Sarantopoulos J, et al. AMG479 monotherapy to treat patients with advanced GI carcinoid tumors: a subset analysis from the first-in-hu man study. 2009 Gastrointestinal Cancers Symposium, 2009:A386.
46. Rajan A, Riely GJ, Carter CA, et al. Phase II study of cixutumumab (IMC-A 12) in thymic malignancies. J Clin Oncol, 2012,30 suppl:abstr 7033.
47. Abou-Alfa GK, Gansukh B, Chou JF, et al. Phase II study of cixutumumab (IMC-A 12, NSC742460; c) in hepatocellular carcinoma (HCC). J Clin Oncol, 2011,29 suppl:abstr 4043.
48. Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol, 2010,65:765-773.
49. Higano C, Alumkal J, Ryan C, et al. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (mAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastatic, asymptomatic castration-re sistant prostate cancer. J Clin Oncol, 2009, 27 suppl: abstr 5142.
50. Higano CS, Alumkal JJ, Ryan CJ, et al. A phase II study of cixutumumab (IMC-A 12), a monoclonal antibody (mAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-re sistant prostate cancer (mCRPC): Feasibility of every 3-w eek dosing and updated results. Genitourinary Cancers Symposium, 2010:Abstract 189. (http://meetinglibrary.asco.org/content/30567-30573)
51. Carden CP, Frentzas S, Langham M, et al. Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-90 6, a small-m olecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors. J Clin Oncol, 2009,27 suppl:abstr 3544.
52. Lindsay CR, Chan E, Evans TR, et al. Phase I OSI-90 6, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol, 2009,27 suppl:abstr 2559.
53. Evans T, Lindsay CR, Chan E, et al. Phase I dose-es calation study of continuous oral dosing of OSI-90 6, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. J Clin Oncol, 2010,28 suppl:abstr 2531.
54. Haluska P, Huang J, Lam B, et al. MEDI-57 3 as a novel approach to IGF-1R and IR-A signaling inhibition by blocking IGF ligands: Phase I PK/PD, safety data, and disease linkage studies in breast cancer. J Clin Oncol, 2011,29 suppl 27:abstr 271.
55. Kindler HL, Richards DA, Stephenson J, et al. A placebo-controlled, randomized phase ii study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol, 2010,28 suppl:abstr 4035.
56. Philip P, Goldman B, Ramanathan R, et al. Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-07 27). J Clin Oncol, 2012,30 suppl:abstr 4019.
57. Lu J, Deng H, Tang R, et al. Exposure-re sponse (E-R) analysis to facilitate phase III (P3) dose selection for AMG 479 (A479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC). J Clin Oncol, 2011,29 suppl 4:abstr 263.
58. Pancreatic cancer: amgen halts phase III trial of ganitumab plus gemcitabine. The Clinical Cancer Letter, 2012,35:3.
59. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-in sulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-sm all-cell lung cancer. J Clin Oncol, 2009,27:2516-2522.
60. Jassem J, Langer CJ, Karp DD, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol, 2010,28 suppl:abstr 7500.
61. Klotz DM, Hewitt SC, Ciana P, et al. Requirement of estrogen receptor-al pha in insulin-like growth factor-1 (IGF-1) induced uterine responses and in vivo evidence for IGF-1/ estrogen receptor cross-ta lk. J Biol Chem, 2002,277:8531-8537.
62. Nicholson RI, Hutcheson IR, Knowlden JM, et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res, 2004,10:346S-354S.
63. Frogne T, Jepsen JS, Larsen SS, et al. Antiestrogen-re sistant human breast cancer cells require activated protein kinase B/ Akt for growth. Endocr Relat Cancer, 2005,12:599-614.
64. Ye JJ, Liang SJ, Guo N, et al. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res, 2003,35:836-842.
65. Robertson JF, Steger GG, Neven P, et al. Activity of fulvestrant in HER2-ov erexpressing advanced breast cancer. Ann Oncol, 2010,21:1246-1253.
66. Camirand A, Zakikhani M, Young F, et al. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res, 2005,7:R570-579.
67. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-ep idermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-ki nase signaling. Cancer Res, 2002,62:200-207.
68. Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res, 2005,65:11118-11128.
69. Jones HE, Gee JM, Taylor KM, et al. Development of strategies for the use of anti-gr owth factor treatments. Endocr Relat Cancer, 2005,12 Suppl 1:S173-182.
70. Ramalingam SS, Spigel DR, Chen D, et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-st age non-small-ce ll lung cancer. J Clin Oncol, 2011,29 suppl:abstr 7527.
71. Belani CP, Goss G, Blumenschein G, Jr. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer treatment reviews, 2012,38:173-184.
72. Watkins DJ, Tabernero J, Schmoll HJ, et al. A randomized phase II/III study of the anti-IGF-1R antibody MK-06 46 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-ty pe (wt) KRAS status. J Clin Oncol, 2011,29 suppl:abstr 3501.
73. Watkins DJ, Ayers M, Cunningham D, et al. Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-06 46) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-ty pe metastatic colorectal cancer (mCRC). J Clin Oncol, 2012,30 suppl:abstr 3531.
74. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res, 2006,66:1500-1508.
75. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of AKT signaling through an IGF-1R-dependent mechanism. Oncogene, 2007,26:1932-1940.
76. Kurmasheva R, Boltz C, Phelps D, et al. Combination of CP-751871, a human monoclonal antibody against the IGF-1 receptor, with rapamycin results in a highly effective therapy for xenografts derived from childhood sarcomas. AACR Meeting Abstracts, Oct 2007: C172.
77. Naing A, LoRusso P, Fu S, et al. Insulin growth factor-re captor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res, 2012,18:2625-2631.
78. Vlahovic G, Meadows K, Arrowood C, et al. Phase I study of the IGF-1R antibody ganitumab (AMG 479) in combination with everolimus in patients with advanced solid tumors. Mol Cancer Ther, 2011,10 Suppl 1:B58.
79. Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol, 2010,28 suppl:abstr 3008.
80. Naing A, LoRusso P, Mills G, et al. Phase I study combining an IGFR inhibitor (IMC-A 12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma. J Clin Oncol, 2009, 27 suppl:abstr e14535.
81. Khawaja MR, Younger A, Funke JM, et al. Phase I study of everolimus (RAD001) and AMG 479 in patients (pts) with advanced solid tumors and colorectal cancer (CRC). J Clin Oncol, 2011,29 suppl:abstr TPS157.
82. Hart L, Burris HA, Infante JR, et al. mTOR inhibitor everolimus (EV) and IGFR inhibitor OSI-90 6 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol, 2011, 29 suppl: abstr e14054.
83. Ahmed SR, Cosgrove D, Ball D, et al. A phase I, single-institution, open-la bel, dose escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A 12 in subjects with advanced solid malignancies. J Clin Oncol, 2012, 30 suppl:abstr 3020.
84. Higano CS, Yu EY, Whiting SH, et al. A phase I, first in man study of weekly IMC-A 12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol, 2007, 25 suppl:abstr 3505.
85. Atzori F, Tabernero J, Cervantes A, et al. A phase I, pharmacokinetic and pharmacodynamic) study of Dalotuzumab (MK-06 46), an insulin-like growth factor-I receptor monoclonal antibody in patients with advanced solid tumors. Clin Cancer Res, 2011,17:6304-6312.
86. Hidalgo M, Tirado Gomez M, Lewis N, et al. A phase I study of MK-06 46, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2wk schedule. J Clin Oncol, 2008, 26 suppl:abstr 3520.
87. Dong J, Tamraz S, Berquist L, et al. BIIB022, a human antibody targeting human insulin-like growth factor-1 receptor (IGF-1R), enhances the anti-tu mor activities of Tarceva in nonsmall cell lung carcinoma (NSCLC) and Rapamycin in sarcoma cell lines. AACR Meeting Abstracts, Apr 2008: 4002.
88. Hariharan K, Dong J, Demarest S, et al. BIIB022, a fully human nonglycosylated gamma-4P antibody targeting IGF-1R for cancer therapy. AACR Meeting Abstracts, Oct 2007: B210.
89. Cartlidge S, Chang Y, Lecomte-Raeber O, et al. MEDI-57 3: a fully human antibody to IGF-I and IGF-II for the treatment of solid tumor and hematological diseases. AACR Meeting Abstracts, Apr 2009: 2802.
90. Carboni JM, Wittman M, Yang Z, et al. BMS-75 4807, a small molecule inhibitor of insulin-like growth factor-1R /IR. Mol Cancer Ther, 2009,8:3341-3349.
91. Girnita A, Girnita L, del Prete F, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res, 2004,64:236-242.
92. + leukemias with either failure to multiple TKI therapies or with T315I mutation. American Society of Hematology Annual Meeting, Dec 2008: A3232.
93. Ryan CJ, Harzstark AH, Rosenberg J, et al. A pilot doseescalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int, 2008,101:436-439.
94. Youngren JF, Gable K, Penaranda C, et al. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and cerbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat, 2005,94:37-46.
95. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-75 1,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol, 2010,11:129-135